Relative Bioavailability of Zongertinib, an Orally Administered HER2-Selective Tyrosine Kinase Inhibitor, under Fed and Fasted Conditions in Healthy Male Participants: Results from Two Randomized, Open-Label, Crossover Studies
Molecular Pharmaceutics · 2025
DOI: 10.1021/acs.molpharmaceut.5c00832 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Hélène Pereira und 11 weiteren Autor:innen. Beteiligte Einrichtung: VennLife Sciences, Lage Mosten 29, 4822 NK Breda, The Netherlands. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Erb-b2 Receptor Tyrosine Kinases, Pyridines. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Boehringer Ingelheim.
Abstract (Originalsprache)
Human epidermal growth factor receptor 2 (HER2), also known as ErbB2, is mutated in various solid tumors. Zongertinib (BI 1810631) is a novel, orally administered, HER2-specific tyrosine kinase inhibitor that spares the epidermal growth factor receptor (EGFR), limiting EGFR-related adverse events. Zongertinib has recently received accelerated approval in the United States and China for patients with advanced, previously treated, HER2 mutant NSCLC. Two Phase I open-label crossover studies evaluated the effect of a high-fat, high-calorie meal on zongertinib bioavailability at two doses: 30 mg (NCT05380947) and 240 mg (NCT06075277). Healthy male participants were randomized to treatment sequences in which they received single doses of zongertinib (spray-dried dispersion formulations) under fed and fasted conditions. The washout interval was ≥14 days. The primary end points were the area under the concentration-time curve of zongertinib in plasma over the time from 0 to the last quantifiable data point (AUC0-tz), and the maximum measured concentration of zongertinib in plasma (Cmax). In NCT05380947, 13 participants received 30 mg of zongertinib. The ratios of adjusted geometric means demonstrated lower AUC0-tz and Cmax, under fed (n = 9) versus fasted (n = 12) conditions (fed/fasted, % [90% CI]: AUC0-tz, 74.2% [67.6-81.6]; Cmax, 53.5% [40.5-70.8]). In NCT06075277, the ratios of adjusted geometric means for AUC0-tz and Cmax were ∼26% higher under fed versus fasted conditions (fed/fasted, % [90% CI]: AUC0-tz, 126.6% [112.1-143.1]; Cmax, 126.1% [106.3-149.6]). In both studies, median tmax was delayed (NCT05380947/NCT06075277) under fed (3/4 h) versus fasted (1.5/2 h) conditions. Zongertinib demonstrated good bioavailability in healthy participants. A small dose-dependent food effect was observed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- VennLife Sciences, Lage Mosten 29, 4822 NK Breda, The Netherlands.
- Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany.
- Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877-0368, United States.
- Staburo GmbH, Aschauer Straße 26a, 81549 Munich, Germany.
- Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Fahrstrasse 17, 91054 Erlangen, Germany.
- Boehringer Ingelheim Pharma GmbH & Co. KG, Binger Str. 173, 55216 Ingelheim am Rhein, Germany.
ORCID-Profile: Behbood Sadrolhefazi, Rolf Grempler, Philipp M Roessner
Förderung
- Boehringer Ingelheim
Zitieren
APA
Pereira, H., Wölke, S., Sadrolhefazi, B., Esmaeili, H., Wind, S., Gan, G., Müller, F., Minich, D., Bader, K., Grempler, R., Law, Y. K., & Roessner, P. M. (2025). Relative Bioavailability of Zongertinib, an Orally Administered HER2-Selective Tyrosine Kinase Inhibitor, under Fed and Fasted Conditions in Healthy Male Participants: Results from Two Randomized, Open-Label, Crossover Studies. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c00832
Vancouver
Pereira H, Wölke S, Sadrolhefazi B, Esmaeili H, Wind S, Gan G, et al. Relative Bioavailability of Zongertinib, an Orally Administered HER2-Selective Tyrosine Kinase Inhibitor, under Fed and Fasted Conditions in Healthy Male Participants: Results from Two Randomized, Open-Label, Crossover Studies. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.5c00832
BibTeX
@article{Pereira2025,
author = {Pereira, Hélène and Wölke, Stefan and Sadrolhefazi, Behbood and Esmaeili, Habib and Wind, Sven and Gan, Guanfa and Müller, Fabian and Minich, David and Bader, Kerstin and Grempler, Rolf and Law, Yeuk Ki and Roessner, Philipp M},
title = {Relative Bioavailability of Zongertinib, an Orally Administered HER2-Selective Tyrosine Kinase Inhibitor, under Fed and Fasted Conditions in Healthy Male Participants: Results from Two Randomized, Open-Label, Crossover Studies},
journal = {Molecular Pharmaceutics},
year = {2025},
doi = {10.1021/acs.molpharmaceut.5c00832}
}
EUVIMED